When several heart medications were found to be contaminated with varying levels of two compounds that are suspected of being human carcinogens, most reports confidently named valsartan as the culprit. Several lots of medications containing valsartan manufactured primarily in Chinese laboratories were found to contain trace amounts of compounds known as NDMA and NDEA. Subsequent testing lead to recalls being issued in both the United States and Canada while ...
Contamination Leads to Cancer Risk in Another Heart Medication
Posted November 15, 2018 in Drug and Medical Device Lawsuits | Product News and Recalls
New Impurity Discovered in Heart Medication
Posted September 27, 2018 in Drug and Medical Device Lawsuits | Product News and Recalls
Several medications containing valsartan, a component of generic medications used to treat high blood pressure and heart failure, were found to be tainted with a chemical impurity earlier this summer. The discovery of NDMA in the drug, a chemical used in everything from rocket fuel to fish processing, led to a voluntary recall of several valsartan-based medications in July.
NDMA, or N-nitrosodimethylamine, is listed as a possible human carcinogen with the EPA. And while not all valsartan-based ...
continue reading...
